OneSource Specialty Pharma Ltd has announced it will host an earnings call on Saturday, July 25, 2026, to discuss the unaudited financial results for the quarter ended June 30, 2026. The conference is scheduled to begin at 10:00 AM IST, providing a platform for analysts and investors to review the company's performance for Q1FY27.

Senior management will lead the interaction, offering insights into the quarterly numbers. The speakers include Neeraj Sharma, CEO & MD, and Anurag Bhagania, CFO. The discussion will focus on the financial outcomes and operational highlights of the period.

Participants can join the call via universal access numbers or through a pre-registration link. The company has provided specific dial-in details to facilitate access for all interested stakeholders.

Conference Call Details

The intimation was filed by Trisha A, Company Secretary and Compliance Officer, on behalf of OneSource Specialty Pharma Limited.

OneSource Specialty Pharma and Formycon AG have formed a strategic manufacturing partnership for biosimilars. Announced on July 14, 2026, the collaboration leverages OneSource's integrated biologics manufacturing capabilities in Bengaluru to support Formycon's biosimilar programs for global markets. This alliance aims to advance global access to cost-effective biologic medicines by combining Formycon's development excellence with OneSource's end-to-end manufacturing expertise.

Under the agreement, OneSource will serve as a strategic manufacturing partner, providing integrated Drug Substance (DS) and Drug Product (DP) capabilities. The partnership aligns with Formycon's FYB4Growth strategy to strengthen supply capabilities through reliable, scalable, and cost-efficient manufacturing. OneSource operates five facilities approved by global regulatory authorities, including the US FDA and EMA, positioning it as a key partner for Formycon's established portfolio and robust pipeline.

Strategic Significance

The partnership underscores the increasing importance of biosimilars in the pharmaceutical sector. By joining forces, the companies aim to leverage their respective expertise to strengthen their position in biosimilars manufacturing. Neeraj Sharma, Managing Director & CEO of OneSource, highlighted that India is uniquely positioned to serve as a global hub for world-class biologics. Dr. Stefan Glombitza, CEO of Formycon AG, emphasized that the addition of OneSource to their network supports their commitment to high standards of quality and operational excellence.